{
    "eid": "2-s2.0-85048732270",
    "title": "Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis",
    "cover-date": "2018-06-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Cardiology and Cardiovascular Medicine",
            "@code": "2705",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "apixaban",
        "atrial fibrillation",
        "bleeding complication",
        "meta-analysis",
        "thromboembolic events",
        "vitamin K antagonist",
        "warfarin"
    ],
    "authors": [
        "Ronpichai Chokesuwattanaskul",
        "Charat Thongprayoon",
        "Tanyanan Tanawuttiwat",
        "Wisit Kaewput",
        "Pavida Pachariyanon",
        "Wisit Cheungpasitporn"
    ],
    "citedby-count": 52,
    "ref-count": 45,
    "ref-list": [
        "Chronic kidney disease increases risk for venous thromboembolism",
        "Increased risk of atrial fibrillation in end-stage renal disease patients on dialysis: A nationwide, population-based study in Taiwan",
        "Renal impairment in patients with thromboembolic event: Prevalence and clinical implications. A systematic review of the literature",
        "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials",
        "Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation",
        "Apixaban versus warfarin in patients with atrial fibrillation",
        "Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: eNGAGE AF-TIMI 48 analysis",
        "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation",
        "Dabigatran versus warfarin in patients with atrial fibrillation",
        "2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association",
        "Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis",
        "Balancing anticoagulation decisions in patients on dialysis with atrial fibrillation",
        "Use of oral anticoagulation in the management of atrial fibrillation in patients with ESRD: Pro",
        "Use of oral anticoagulation in the management of atrial fibrillation in patients with ESRD: Con",
        "The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies",
        "Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement",
        "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses",
        "Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review",
        "Meta-analysis in clinical trials",
        "Measuring inconsistency in meta-analyses",
        "Publication bias in clinical research",
        "Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease",
        "Evaluation of apixaban in patients on dialysis",
        "Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment",
        "A multicenter analysis of factors associated with apixaban-related bleeding in hospitalized patients with end-stage renal disease on hemodialysis",
        "Anticoagulant use and associated outcomes in patients with atrial fibrillation and advanced kidney disease",
        "Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin",
        "Oral apixaban for the treatment of acute venous thromboembolism",
        "Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views",
        "Atrial fibrillation in CKD: Balancing the risks and benefits of anticoagulation",
        "Dilemmas in the management of atrial fibrillation in chronic kidney disease",
        "Endothelium-dependent contractions in hypertension",
        "Unfractionated heparin for hemodialysis: Still the best option",
        "Apixaban pharmacokinetics at steady state in hemodialysis patients",
        "Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD",
        "Patterns of initiation of oral anticoagulants in patients with atrial fibrillation\u2014quality and cost implications",
        "Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: An evidence-based review",
        "Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)",
        "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS",
        "Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy",
        "Warfarin use in hemodialysis patients: What is the risk",
        "Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation",
        "Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation",
        "Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Jackson",
            "@id": "60004109",
            "affilname": "University of Mississippi Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004109",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Lubbock",
            "@id": "60032964",
            "affilname": "Texas Tech University Health Sciences Center at Lubbock",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032964",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60006964",
            "affilname": "Phramongkutklao College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006964",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Cooperstown",
            "@id": "60002688",
            "affilname": "The Mary Imogene Bassett Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002688",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}